Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2006-09-12
2006-09-12
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
Reexamination Certificate
active
07105576
ABSTRACT:
The present invention provides methods of inhibiting metastasis of a tumor and methods of treating a tumor using a combination of an inhibitor of the activation of nuclear factor NF-κB and a cancer chemotherapeutic agent. In one embodiment of the present invention, combination of curcumin and paclitaxel (taxol) can be used to treat and inhibit metastasis of breast tumor.
REFERENCES:
patent: 5891924 (1999-04-01), Aggarwal
patent: 2001/0025034 (2001-09-01), Arbiser
patent: 2002/0019382 (2002-02-01), Snyder et al.
patent: 2002/0035090 (2002-03-01), Zeldis
patent: 2004/0058021 (2004-03-01), Aggarwal
patent: 2005/0049299 (2005-03-01), Aggarwal
PubMed, Miller et al, Clin Breast Cancer, Oct. 2001 2(3) 236, abstract.
Medline AN94201161, Arbuck, et al, Hematology/oncology clinics of N Am, 1994.
Brennan et al., “Inhibition of nuclear factor κB by direct modification in whole cells—mechanism of action of nordihydroguaiaretic acid, curcumin and thiol modifiers,”Biochem. Pharmacol.,55:965-973, 1998.
Cheng et al., “Phase I chemoprevention clinical trail of curcumin,,”Proc. Am. Soc. Clin. Oncol.17:558a, 1998.
Estrov et al., “Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells,”Blood,94:2844-2853, 1999.
Feinman et al., “Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2,”Blood,93:3044-3052, 1999.
Giri and Aggarwal, “Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates,”J. Biol. Chem.,273:14008-14014, 1998.
Han et al., “Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53,”Clin. Immunol.,93:152-161, 1999.
Hour et al., “Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation,” Prostate, 51:211-218, 2002.
Huang et al., “Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice,”Carcingenesis,19:1697-1700, 1998.
Ichiki et al., “Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer,”Clin. Exp. Metastasis,18:539-545, 2001.
Inano et al., “Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays,”Carcingenesis,20:1011-1018, 1999.
Jaffe et al., “Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma,” N.Engl. J. Med.,291:994-997, 1974.
Jang et al., “A curcuminoid and sesquiterpenes as inhibitors of macrophage TNF-alpha release from Curcuma zedoaria,”Planta Med.67:550-552, 2001.
Jaruga et al., “Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes,”FEBS Lett.,433(3):287-293, 1998.
Jobin et al., “Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity,” J. Immunol., 163:3474-3483, 1999.
Kawamori et al., “Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer,” Cancer Res. 59:597-601, 1999.
Kumar et al., “Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation,”Biochem. Pharmacol.,55:775-783, 1998.
Mehta et al., “Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines,”Anti-Cancer Drugs,8:470-481, 1997.
Menon et al, “Anti-metastatic activity of curcumin and catechin,”Cancer Lett.,141:159-165, 1999.
Mohan et al., “Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B,”J. Biol. Chem,275:10405-10412,2000.
Navis et al., “Dietary curcumin with cisplatin administration modulates tumour marker indices in experimental fibrosarcoma,”Pharmacol. Res.,39:175-179, 1999.
Ni et al., “Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis,”Br. J. Haematol.115:279-286, 2001.
Pahl et al., “Activators and target genes of Rel/NF-kappaB transcription factors,”Oncogene,18:6853-6866, 1999.
Pan et al., “Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages,”Biochem. Pharmacol.,60:1665-1676, 2000.
Plummer et al., “Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex,”Oncogene,18:6013-6020, 1999.
Podar et al., “Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells,”J. Biol. Chem.,278(8):5794-801, 2002.
Ramachandran et al., “Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin,”Breast Cancer Res. and Treat.,54:269-278, 1999.
Rao et al., “Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound,”Cancer Res.,55:259-266, 1995.
Shishodia and Aggarwal, “Nuclear factor-B activation: a question of life and death,”J. Biochem Mol. Biol.,35:28-40, 2002.
Simon et al., “Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships,”Cancer Lett.,129:111-116, 1998.
Singh and Aggarwal, “Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane)”J. Biol Chem.,270:24995-25000, 1995.
Singletary et al., “Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin,”Cancer Lett.,103:137-141, 1996.
Sonneveld et al., “Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914),”Br. J. Haematol.,115(4):895-902.
Westerheide et al., “The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transitiion”Mol. Cell. Biol.21:8428-8436, 2001.
Zhang et al., “” Zhongguo Yaolixue Tongbao, 17(6):702-704, 2001 (Abstract).
Zhang et al., “Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells,”Carcinogenesis,20:445-451, 1999.
Zhang et al., “Tyrosine kinase inhibitor emodin suppresses growth of HER-2
eu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel,”Clin. Cancer Res.,5:343-353, 1999.
Fulbright & Jaworski L.L.P.
Gembeh Shirley V.
Low Christopher S. F.
Research Development Foundation
LandOfFree
Synergistic effects of nuclear transcription factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic effects of nuclear transcription factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic effects of nuclear transcription factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528752